Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]
Discontinued
Reference number: GID-TAG444
Following on from information provided to NICE by the company in April 2014, the appraisal of Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.